Rhumbline Advisers Sells 2,115 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Rhumbline Advisers decreased its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 2.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,535 shares of the company's stock after selling 2,115 shares during the quarter. Rhumbline Advisers owned 0.24% of Inspire Medical Systems worth $11,394,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Smartleaf Asset Management LLC lifted its position in shares of Inspire Medical Systems by 178.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 357 shares of the company's stock valued at $66,000 after acquiring an additional 229 shares in the last quarter. Mutual of America Capital Management LLC grew its stake in Inspire Medical Systems by 1.2% during the 4th quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company's stock valued at $842,000 after acquiring an additional 55 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Inspire Medical Systems by 11.3% in the 4th quarter. Jones Financial Companies Lllp now owns 2,075 shares of the company's stock valued at $385,000 after acquiring an additional 210 shares during the last quarter. New York State Teachers Retirement System increased its holdings in shares of Inspire Medical Systems by 13.6% in the fourth quarter. New York State Teachers Retirement System now owns 9,194 shares of the company's stock valued at $1,704,000 after purchasing an additional 1,100 shares during the last quarter. Finally, WCM Investment Management LLC acquired a new position in Inspire Medical Systems during the fourth quarter worth $10,291,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of recent analyst reports. Royal Bank of Canada decreased their price objective on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a report on Tuesday, April 15th. Wells Fargo & Company reduced their target price on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price objective on Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. KeyCorp reduced their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Robert W. Baird boosted their target price on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $211.91.

Insider Buying and Selling at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 360 shares of Inspire Medical Systems stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $160.00, for a total transaction of $57,600.00. Following the completion of the sale, the director now owns 24,046 shares of the company's stock, valued at approximately $3,847,360. This trade represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Price Performance

INSP stock traded down $1.75 on Friday, reaching $126.86. The company's stock had a trading volume of 983,733 shares, compared to its average volume of 566,018. Inspire Medical Systems, Inc. has a 52 week low of $123.00 and a 52 week high of $225.00. The company has a market capitalization of $3.74 billion, a P/E ratio of 73.33, a price-to-earnings-growth ratio of 2.86 and a beta of 1.28. The firm has a fifty day moving average of $147.79 and a two-hundred day moving average of $170.29.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. The company had revenue of $201.32 million for the quarter, compared to analysts' expectations of $194.89 million. During the same period last year, the firm earned ($0.34) EPS. The firm's revenue for the quarter was up 22.7% on a year-over-year basis. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.